Indo Us Biotech logo

Indo Us Biotech financials and balance sheet

NSE: INDOUSBSE: 541304Agricultural Food & other ProductsSmall Cap

Last close ₹63.80down ₹4.13 (6.08%)BSE ₹63.50

Share price at the NSE close on 23 Oct 2026. Previous close ₹67.93.

52-week range of traded prices to 23 Oct 2026
₹61.10Low, 23 Oct 2026₹159.00High, 27 Nov 2025
Market cap
₹128 Cr2,332nd largest listed
P/E
11.2
P/B
1.4
Dividend yield
Nonein the last 12 months
ROE
13.4%
ROCE
11.2%
Debt to equity
0.40
Volume, NSE
6,16566.5% delivered

9 years at a glance

Standalone: the listed company alone, without its subsidiaries. ₹ crore, years to March.Indo Us Biotech annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
Peak revenue ₹110 Cr, year to Mar 2026

Operating and net margin, per cent

  • Operating margin
  • Net margin

Results for the year to Mar 2026

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue110
  2. Materials and goods−80
  3. Employee costs−1.4
  4. Other expenses−12
  5. Operating profit17
  6. Depreciation−0.9
  7. Other income+0.1
  8. One-off items0.0
  9. Finance costs−2.2
  10. Profit before tax14
  11. Tax−0.8
  12. Net profit13

What the company owns

  • Inventory₹100 Cr
  • Receivables₹14 Cr
  • Plant, investments and other assets₹13 Cr
  • Cash and bank₹6 Cr

What pays for it: net worth and liabilities

  • Net worth₹93 Cr
  • Borrowings₹37 Cr
  • Other liabilities₹3 Cr
  • Owed to suppliers₹0 Cr

Profit and loss

Standalone, ₹ crore, years to March. The years to Mar 2019 and Mar 2020 are not shown: their results were filed at the wrong scale, a power of ten off the company's own year-to-date figures.Indo Us Biotech quarterly results

₹ croreMar 2018Filed 25 JulMar 2019Mar 2020Mar 2021Mar 2022Filed 25 MayMar 2023Filed 10 MayMar 2024Filed 25 JunMar 2025Filed 19 JunMar 2026Filed 29 May
Revenue from operations30––40506273104110
–––354352628593
Materials and goods bought23––03645−207380
Employee costs––––12111
Other expenses––––66801112
Operating profit before depreciation–––679111917
Operating margin–––13.8%13.8%15.2%14.8%18.2%15.4%
Materials, % of revenue––––72.3%73.1%−26.9%70.0%72.7%
Employee costs, % of revenue––––1.4%2.5%1.6%1.1%1.3%
Other expenses, % of revenue––––12.5%9.3%110.5%10.7%10.6%
Depreciation and amortisation–––001111
Operating profit after depreciation–––569101816
Other income0––000000
Finance costs1––111212
Profit before one-off items and tax2––45791714
One-off items––––0––00
Profit before tax2––45791714
1––−100101
Net profit1––55781613
Other comprehensive income––––0––00
Total comprehensive income––––5––1613
Net margin4.9%––12.7%10.5%11.7%11.3%15.7%11.9%
Materials, employee costs and other expenses are shown for the years they add up to operating expenses; for the year to Mar 2021 they do not, so they are left blank. Operating expenses, operating profit before depreciation and operating profit after depreciation are left blank for the year to Mar 2018: the statement does not state its depreciation, which operating profit is worked out from, so operating profit is not given.

Balance sheet

Standalone, ₹ crore, at 31 March.

₹ croreMar 2018Filed 25 JulMar 2019Mar 2020Mar 2021Mar 2022Filed 25 MayMar 2023Filed 10 MayMar 2024Filed 25 JunMar 2025Filed 19 JunMar 2026Filed 29 May
5–––3954637993
Share capital3–––910202020
Reserves2–––3044435872
7–––1312141537
10–––1212171640
2–––43431
Total assets17–––56698498133
2–––910111112
15–––47607387121
Net debt6–––1211131531
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the year to Mar 2021, so its lines and the ratios worked from it are blank there.

Cash flow

Standalone, ₹ crore, years to March.

₹ croreMar 2022Filed 25 MayMar 2023Filed 10 MayMar 2024Filed 25 JunMar 2025Filed 19 JunMar 2026Filed 29 May
2.90.5−4.6−1.4−16.1
3.30.8−4.30.4−15.6
−3.8−8.6−15.4−17.3−30.9
Receivables4.2−4.25.83.6−0.9
Inventories−11.5−3.6−24.8−19.0−29.3
Payables3.2−0.83.0−3.2−0.7
Other working capital0.30.00.71.3−0.1
Tax paid−0.4−0.3−0.3−0.4−0.4
Interest paid0.00.00.0−1.50.0
Capital spending4.01.82.60.02.4
Free cash flow−1.1−1.3−7.2−1.4−18.5
5.46.74.3−0.83.3
5.17.11.2−1.524.4
Dividends paid0.20.00.00.50.0
Shares bought back0.0––0.00.0
Shares issued2.78.40.00.00.0
Net change in cash13.414.30.9−3.711.6
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2018 and Mar 2021.

Per share

Standalone, ₹ per share, years to March.Indo Us Biotech dividend history

₹ per shareMar 2018Filed 25 JulMar 2019Mar 2020Mar 2021Mar 2022Filed 25 MayMar 2023Filed 10 MayMar 2024Filed 25 JunMar 2025Filed 19 JunMar 2026Filed 29 May
Earnings per share₹4.23––₹8.40₹8.59₹7.51₹4.11₹8.12₹6.54
Diluted earnings per share₹4.23––₹8.40₹8.59₹7.51₹4.11₹8.12₹6.54
Dividend per share–––––––₹0.25–
Book value per share₹14.43–––₹53.39₹54.35₹31.29₹39.16₹46.15
Dividend payout–––––––3.1%–
Shareholder yield––––−5.2%−3.9%0.0%0.2%0.0%
Market cap at the year end (₹ crore)–––2049213445299197

Ratios

Standalone, years to March.Indo Us Biotech PE ratio and valuation

RatioMar 2018Filed 25 JulMar 2019Mar 2020Mar 2021Mar 2022Filed 25 MayMar 2023Filed 10 MayMar 2024Filed 25 JunMar 2025Filed 19 JunMar 2026Filed 29 May
Revenue growth––––24.9%23.4%18.0%42.6%6.4%
Operating profit growth––––25.5%35.5%15.1%75.4%−10.2%
Net profit growth––––2.7%38.2%14.0%97.1%−19.3%
Earnings per share growth––––2.3%−12.6%−45.3%97.6%−19.5%
29.3%–––13.5%15.5%14.1%23.0%15.3%
–––––2.0 pts−1.4 pts9.0 pts−7.7 pts
From the net margin–––––1.6 pts−0.5 pts5.4 pts−5.6 pts
From asset turnover–––––1.5 pts−0.6 pts4.0 pts−2.8 pts
From borrowing–––––−1.0 pts−0.3 pts−0.4 pts0.7 pts
Return on capital employed––––12.6%12.9%13.0%19.1%12.4%
Cash conversion––––55.5%7.3%−55.5%−8.7%−122.6%
Interest cover–––4.55.57.26.612.07.2
Debt to equity1.32–––0.320.210.230.190.40
Receivable days111–––150146955345
Inventory days98–––236218−964355455
Payable days––––26––62
Cash conversion cycle, days––––360––402498
Working capital days117–––318339331288367
Asset turnover1.73–––0.900.990.951.140.96
Assets per rupee of net worth3.47–––1.431.341.311.291.35
Sales per rupee of plant19.73–––9.047.076.9610.159.85
Capital spending to depreciation––––9.072.213.260.002.67
Plant being built, % of plant in use––––42.0%–––4.5%
No balance sheet is on record for the year to Mar 2021, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2026.

Return on assets, latest year
11.4%
Cash from operations against operating profit
−94.6%
Measure5 years3 years
Revenue growth, yearly rate22.5%21.4%
Profit growth, yearly rate20.8%21.9%
Return on equity, average16.3%17.5%
Return on capital employed, average14.0%14.8%
Operating margin, average15.5%16.2%
Net margin, average12.2%13.0%
Asset turnover, average0.991.01
Cash conversion cycle, days, average–450
Interest cover, average7.78.6
Debt to equity, average0.270.27

Where the cash came from and went

Standalone: the listed company alone, without its subsidiaries. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations−18.7−22.1−16.1
Cash from investing18.86.83.3
Cash from financing36.324.224.4
Capital spending10.85.02.4
Dividends paid0.70.50.0
Shares bought back––0.0
Shares issued for cash11.10.00.0
Borrowings raised–5.22.0
Borrowings repaid–24.224.2

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9––––––––3
Altman Z-scorePublished threshold 1.81–––––––12.645.64
Beneish M-scorePublished threshold −1.78––––––––−1.70
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets–––––––20.2722.46
Receivables growth less revenue growthOur threshold 0 percentage points–––––−2.91−40.99−63.80−14.64
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–––––−9.53235.65−434.2830.93
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–––––12.98−9.41−0.410.06
Assets under construction, years of additionsOur threshold 2 years of additions––––––––0.27
Effective tax ratePublished threshold 17.16 per cent28.98––––1.986.281.595.73
Tax charged less tax paid, % of profitOur threshold 10 percentage points–––––−2.282.75−0.532.57
A threshold marked as ours has no published figure; it is the line we read the check against.